NCT00596635

Brief Summary

Urinary tract infections (UTIs) affect over 7 million men and women per year and cost the health care industry over 1 billion dollars annually. The incidence of UTI increases markedly in elderly institutionalized persons and leads to excessive antimicrobial usage, emergency room visits, hospitalization, sepsis, and death. The use of antimicrobials to prevent UTI in elderly nursing home patients is not recommended and is fraught with problems such as adverse reactions, drug interactions, and the development of drug-resistant organisms. There is no accepted method of preventing UTI in residents of nursing homes, a vulnerable and understudied population with significant morbidity from UTI. The overall goal of this proposal is to conduct a prospective cohort pilot study that evaluates the feasibility of using cranberry to prevent UTI in nursing home residents. Each of the aims is critical for the optimal design of a larger placebo-controlled, definitive trial of cranberry for prevention of UTI in nursing home residents and will provide the essential preliminary data for future larger studies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 8, 2008

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 17, 2008

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2008

Completed
2.1 years until next milestone

Results Posted

Study results publicly available

September 23, 2010

Completed
Last Updated

March 29, 2013

Status Verified

March 1, 2013

Enrollment Period

1.6 years

First QC Date

January 8, 2008

Results QC Date

June 30, 2010

Last Update Submit

March 19, 2013

Conditions

Keywords

UTIelderlypreventioncranberryE.Coli

Outcome Measures

Primary Outcomes (1)

  • Number of Urine Cultures Collected Out of the Total Number Expected to be Collected.

    Urine cultures were collected at baseline and monthly for six months. The total number of urine cultures collected out of the total number that were expected to be collected are shown.

    6 months

Secondary Outcomes (2)

  • Number of Participants With E.Coli Isolated From Urine Culture

    6 months

  • Number of Participants With >100,000 Colony Forming Units Per Milliliter of Any Organism Isolated From Urine Culture

    6 months

Study Arms (3)

Control Group

NO INTERVENTION

No cranberry capsules administered

One cranberry capsule

ACTIVE COMPARATOR

1 650mg cranberry capsule daily

Dietary Supplement: Once Daily Cranberry Capsule

Two cranberry capsules

ACTIVE COMPARATOR

1 650 mg cranberry capsule twice daily (bid)

Dietary Supplement: Twice Daily Cranberry Capsules

Interventions

650mg capsule pure cranberry powder

Also known as: Theralogix: Theracran cranberry supplement, 650mg capsule
One cranberry capsule

One 650mg cranberry capsule administered twice per day

Also known as: Theralogix: Theracran cranberry supplement, 650mg capsule
Two cranberry capsules

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Greater than 60 years old and a resident of the nursing home or assisted living facility for greater than 30 days duration

You may not qualify if:

  • Having a known major anatomic abnormality of the urinary tract
  • Presence of acute UTI symptom
  • Intolerance or allergy to cranberry products
  • Current use of cranberry for prevention of UTI
  • Use of warfarin
  • History of kidney stones
  • Presence of a chronic indwelling bladder catheter
  • Dialysis dependence
  • Chronic suppressive antibiotics
  • Immunocompromised state due to hematological malignancies, HIV infection, chronic high dose (\>10mg daily) prednisone or equivalent steroid use.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yale University School of Medicine, Internal Medicine, Section of Infectious Diseases

New Haven, Connecticut, 06511, United States

Location

Related Publications (3)

  • Juthani-Mehta M, Perley L, Chen S, Dziura J, Gupta K. Feasibility of cranberry capsule administration and clean-catch urine collection in long-term care residents. J Am Geriatr Soc. 2010 Oct;58(10):2028-30. doi: 10.1111/j.1532-5415.2010.03080.x. No abstract available.

  • Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Nov 10;11(11):CD001321. doi: 10.1002/14651858.CD001321.pub7.

  • Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Apr 17;4(4):CD001321. doi: 10.1002/14651858.CD001321.pub6.

MeSH Terms

Conditions

Urinary Tract InfectionsEscherichia coli Infections

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesEnterobacteriaceae InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and Mycoses

Limitations and Caveats

The inability to follow all participants for the full six months reflects the vulnerability of the population.

Results Point of Contact

Title
Manisha Juthani-Mehta, MD
Organization
Yale University School of Medicine

Study Officials

  • Manisha Juthani-Mehta, MD

    Yale University School of Medicine, Assistant Professor

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 8, 2008

First Posted

January 17, 2008

Study Start

January 1, 2007

Primary Completion

August 1, 2008

Study Completion

August 1, 2008

Last Updated

March 29, 2013

Results First Posted

September 23, 2010

Record last verified: 2013-03

Locations